Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13862942 | 1.00 | KCNA5 (0.52) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL817770 | 1.00 | KCNA5 (0.52) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL10247782 | 1.00 | KCNA5 (0.52) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| Nitric Acid SCHEMBL27472694 | 0.86 | CYP1A2 (0.44) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL20034107 | 0.83 | KCNA5 (0.53) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL22060302 | 0.83 | KCNA5 (0.53) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL16477945 | 0.83 | KCNA5 (0.53) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL1156021 | 0.83 | KCNA5 (0.53) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL11575817 | 0.83 | KCNH2 (0.45) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL14438700 | 0.83 | TSHR (0.51) | KCNA5KCNH2TSHRKCNE1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220056022-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20200397760-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20190194182-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-3483143-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen, Inc (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9233979-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2927213-A1 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | Amgen Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8569341-B2 | Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2011153509-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011796-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885TSHR 4432/4885 |
| US-20200397760-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | RAD51, MRE11, RAD52 | KCNA5 4838/4885KCNH2 4807/4885TSHR 3938/4885 |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | KCNA5 4418/4885KCNH2 4428/4885TSHR 3122/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | KCNA5 1247/4885KCNH2 2165/4885TSHR 4177/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | KCNA5 4311/4885KCNH2 4796/4885TSHR 2055/4885 |
| US-20160137667-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885TSHR 4432/4885 |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | KCNA5 765/4885KCNH2 1158/4885TSHR 367/4885 |
| US-20220056022-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | KCNA5 4682/4885KCNH2 4755/4885TSHR 3630/4885 |
| US-20190194182-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | KCNA5 4682/4885KCNH2 4755/4885TSHR 3630/4885 |
| US-20140315895-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885TSHR 4432/4885 |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885TSHR 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.